Shanghai Junshi Bioscience Co., Ltd.

This is a first-in-human study to test the safety and find the right dose of an experimental drug called JS207 in people with advanced cancer. It involves 98 patients whose cancer has progressed despite standard treatments. The main goals are to understand the drug's side effects…

This early-stage study is testing a new drug called JS203 in people with B-cell non-Hodgkin's lymphoma that has returned or hasn't responded to previous treatments. The main goals are to find a safe dose, see how the body processes the drug, and check for any early signs that it …

This study is testing if adding a new immunotherapy drug (toripalimab) to an existing cancer drug (lenvatinib) works better than lenvatinib alone for people with advanced liver cancer. It is a large, late-stage trial involving 530 participants who have not had prior systemic trea…